Background: Hepatitis C virus (HCV)-related liver disease has emerged as one of the most important causes of morbidity and mortality in HIVinfected persons. Compared to persons with just one infection, HIV/HCV-coinfected persons have a higher incidence of all liver complications and eve some extrahepatic conditions raising the possibility of multiple pathogenic interactions. HCV can be cured, even without interferon alfa, and HCV drug development is an exceedingly active basic and clinical research field. Medications are in trials that target nearly all major steps in replication. Highlyefficacious, single-tablet, 8-12 week, pangenotypic therapies are already in development. Cure of infection reduces the incidence of liver disease complications and improves mortality. Cure rates among HIV/HCV coinfected persons are equivalent to those with just HCV. Nonetheless, there remain enormous public health challenges. No more than 5% of the ~170 million persons has been prescribed treatment; no more than 10% worldwide and 50% in the US know their infection status. Moreover, most HCV treatment courses exceed $100,000 and yet their effectiveness can be completely abrogated by nonadherence or reinfection. Thus, models of disease control underscore the importance of coupling prevention with treatment. Conclusions: 25 years after discovery of HCV, everything has changed for the 5% in care. But, enormous challenges remain and are even more urgent given the potential to cure.